Sorry for sounding like a pedant, but I’m not letting the company off the hook on this one.
Re the expanded breast cancer animal model studies testing the activity of OmoMyc fused to a cell penetrating Phylomer, the company said on 1 October We expect to report results early Q4 2015.
Re the studies to confirm proprietary Phylomer hits against Myc, the company said on 1 October Results from these studies will be reported early Q4 2015.
“Early” means near the beginning; midway through something is not “early” by any dictionary’s definition or anyone’s interpretation. Nor is being a biotech an excuse to use language in a misleading fashion.
If the company were to report results from these studies after October that, by any definition, would no longer be “early” in Q4 and it would be inexcusable, in my view, given the close proximity of the timing of the guidance to the anticipated timing of reporting.
PYC Price at posting:
1.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)